In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novartis gets rights to Arakis and Vectura's AD237

Executive Summary

Novartis AG has been granted worldwide development and market rights to Arakis Ltd.'s (oncology and inflammatory diseases) and Vectura Ltd.'s (formulation technologies) AD237 (glycopyrronium bromide), a drug candidate in Phase II studies for chronic obstructive pulmonary disease (COPD).
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register